SEC Filing Timeline
8-KOct 06, 2026
Shareholder vote results · Items 5.07
8-KSep 23, 2026
Shareholder vote results · Items 5.07
8-KSep 08, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
DEFA14AAug 14, 2026
Additional proxy
10-QAug 06, 2026
Quarterly report
8-KAug 06, 2026
Earnings release · Items 2.02,9.01
DEFA14AJul 30, 2026
Additional proxy
DEF 14AJul 30, 2026
Proxy statement
8-KJul 13, 2026
Other material event · Items 8.01,9.01
8-KJun 11, 2026
Other material event · Items 5.07,8.01
8-KJun 03, 2026
Executive officer change · Items 5.02
8-KMay 14, 2026
Executive officer change · Items 5.02,8.01
8-KMay 14, 2026
Unregistered share issuance · Items 2.03,3.02,7.01,9.01
10-QMay 08, 2026
Quarterly report
8-KMay 07, 2026
Unregistered share issuance · Items 1.01,1.02,2.02,2.03,3.02,9.01
Recent News (Finnhub)
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen to Participate in Upcoming Scientific Conferences
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifyin…
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas…